Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XL888 · 1 trial · 15 indications
Summary statistics will be presented. Toxicities will be presented as worst toxicity per patient and will be reported as percent toxicity.
| Arm | Type | Description |
|---|---|---|
| Treatment (pembrolizumab, XL888) | EXPERIMENTAL | Patients receive pembrolizumab IV over 30 minutes on day 1 and XL888 PO on days 1, 4, 8, 11, 15, and 18. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. |
| Name | Type | Description |
|---|---|---|
| XL888 | DRUG | Given PO |
| Pembrolizumab | BIOLOGICAL | Given IV |
Inclusion Criteria: * Patients with stage IV or locally advanced unresectable gastrointestinal adenocarcinomas (gastric, gastroesophageal junction \[GEJ\], cholangiocarcinoma, hepatocellular, pancreas, colorectal, small intestinal tumors) who have failed at least one prior therapy (dose escalation ...
XL888 is an investigational small molecule being studied for the treatment of advanced gastrointestinal cancers, including colorectal adenocarcinoma and pancreatic adenocarcinoma. It is being evaluated in combination with pembrolizumab for patients with metastatic, recurrent, or unresectable forms of these diseases.
XL888 is being developed by Exelixis, Inc., a biopharmaceutical company traded on NASDAQ under the ticker EXEL. The company is conducting clinical research to evaluate the drug's safety and efficacy in oncology.
XL888 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. A Phase 1 trial studying XL888 in combination with pembrolizumab has been completed.
XL888 has been studied in one clinical trial, NCT03095781, titled 'Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer.' This Phase 1 trial enrolled 49 participants in the United States and has been completed.
Yes, XL888 is being studied in colorectal adenocarcinoma. The completed Phase 1 trial NCT03095781 included patients with recurrent, stage III, and stage IV colorectal cancer, as well as other advanced gastrointestinal malignancies.